GLP-1 RAs closely associated with increased risk of developing incident diabetic retinopathy: JAMA
Doctor’s Role Uncovered in Smuggling Operation
A new study published in the Journal of American Medical Association found that the use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) was linked to a little rise in incident diabetic retinopathy (DR), while fewer individuals needed invasive treatments, incurred problems from DR, or saw their DR escalate to sight-threatening levels.
A higher incidence of diabetic retinopathy and nonarteritic anterior ischemic optic neuropathy (NAION) is linked to GLP-1 RAs. There is little research on the possibility of sight-threatening effects linked to GLP-1 RAs. Thus, this study was set to find out if using GLP-1 RAs in T2D patients is linked to the emergence of DR, NAION, or DR sequelae.
Using the TriNetX database, this retrospective cohort analysis was carried out from January 1, 2015, to September 30, 2022, on persons (≥18 years old) with T2D who had a recent hemoglobin A1c level of 6.5% or above. Using propensity score matching (PSM) to account for baseline characteristics, the cohort was split into 2 groups according to whether or not the participants were prescribed a GLP-1 RA. On October 10, 2024, the statistical analysis was carried out. The primary endpoint, the relationship between GLP-1 RAs and the probability of incident DR, NAION, or sight-threatening sequelae over a 2-year follow-up period, was assessed using Cox proportional hazard regression models.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.